If it was CD10 for mild / moderate, I could understand the
If it was CD10 for mild / moderate, I could understand the FDA maybe wanting to see some more data there.. I don't think they want any more slots filled in M/M though; there are quite a few already, and the patient population generally doesn't exhibit a dire need.
But you're right, OLE under CD12 makes no sense to me. Unless CD16 is going to be looking at more specific, narrower cohorts than CD12, and that would allow the rest of severe/critical access But then there's still overlap.
Assuming that will be a CC question.
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...
Continue Reading
A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...
Continue Reading
IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...
Continue Reading
Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...
Continue Reading
Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...
Continue Reading
Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...
Continue Reading
The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...
Continue Reading
Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...
Continue Reading
The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...
Continue Reading
In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...
Continue Reading
Top 5 Most Recently Viewed Articles
Overview of the Investigation into RxSight, Inc. Robbins LLP, a respected law firm specializing in shareholder rights, has initiated an investigation into potential breaches of fiduciary duties by the officers and directors of RxSight, Inc. This medical technology company, noted for its innovative light adjustable intraocular lenses used in cataract surgeries, is now...
Continue Reading
Man Group PLC's Public Disclosure on Deliveroo Holdings Recently, Man Group PLC has disclosed significant information regarding their holdings and interests in Deliveroo plc. This action reflects the increasing transparency required under financial regulations aimed at ensuring fair play in the market. Stakeholders and investors alike are keenly observing these...
Continue Reading
Overview of the Synthetic Biology Market The global synthetic biology market is set for remarkable growth, with forecasts showing an increase from US$ 14.5 billion in 2024 to US$ 126.9 billion by 2034. This impressive growth represents a compound annual growth rate (CAGR) of 24.2% over the next decade, underscoring the growing significance of this field across various...
Continue Reading
Significant Opportunity for Quantum Computing Investors Investors of Quantum Computing Inc. (NASDAQ: QUBT) should take note of an important opportunity to participate in a class action lawsuit aimed at addressing substantial losses. This lawsuit has been initiated by Bronstein, Gewirtz & Grossman LLC, a reputable law firm known for its expertise in investor protection....
Continue Reading
Understanding the Fiserv Class Action Lawsuit Investors in Fiserv, Inc. have significant details to grasp concerning an ongoing class action lawsuit. This legal action runs the course of securities fraud allegations that have raised concerns among stakeholders. The importance of timely action cannot be overstated as investors look to protect their interests. Allegations...
Continue Reading